FGFR3 testing in bladder cancer: Recording now available
In our latest Lab Talk, Dr. Michael Hubank delved into FGFR genomic alterations and their role in cancer, specifically focusing on the clinical utility of FGFR3 alterations in bladder cancer patients. FGFR3 alterations which includes genomic alterations and fusions are especially common in bladder cancer, making FGFR3 a key biomarker for targeted treatment. The session covered the importance of FGFR3 diagnostic journey for bladder cancer patients.
Watch the recording now!
Furthermore, Dr. Hubank discussed major diagnostic pitfalls that labs should consider when testing for FGFR3 in bladder cancer, including considerations on test selection, sample quality, and interpretation of results. The event also included a Q&A session at the end.
Access this Lab Talk to deep dive into these topics and learn more about FGFR3 diagnostic.
Download the Lab Talk slides
Click here to download the FAQs from this session!
Dr. Michael Hubank has worked in Genomics for over 20 years. Following a PhD at UCL, he worked at the University of Sussex and Yale University before returning to the UCL Institute of Child Health in 2000 to found and run UCL Genomics. In 2016 he moved into clinical diagnostics at the Royal Marsden Hospital, London, to lead a translational laboratory focused on the development and clinical application of genomic assays for cancer diagnostics. Since 2018 he has been Scientific Director at the NHS England North Thames Genomic Laboratory Hub.
He is a joint investigator on several research projects using multiomic profiling for optimising personalised diagnostics and treatments for childhood cancer patients. He has a strong focus on developing and applying genomic assays, and a particular interest in moving circulating biomarkers into standard of care testing.
Approval code: EM-167190